Literature DB >> 21935923

Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants.

Karen M Kaluza1, Jill M Thompson, Timothy J Kottke, Heather C Flynn Gilmer, Darlene L Knutson, Richard G Vile.   

Abstract

Adoptive T cell therapy has been proven effective against melanoma in mice and humans. However, because most responses are incomplete or transient, cures remain rare. To maximize the efficacy of this therapy, it will be essential to gain a better understanding of the processes which result in tumor relapse. We studied these processes using B16ova murine melanoma and adoptive transfer of OT-I T cells. Transfer of T cells as a single therapy provided a significant survival benefit for mice with established subcutaneous tumors. However, tumors which initially regressed often recurred. By analyzing tumors which emerged in the presence of a potent OT-I response, we identified a novel tumor escape mechanism in which tumor cells evaded T cell pressure by undergoing major genomic changes involving loss of the gene encoding the target tumor antigen. Furthermore, we show that these in vivo processes can be recapitulated in vitro using T cell/tumor cell co-cultures. A single round of in vitro co-culture led to significant loss of the ova gene and a tumor cell population with rapidly induced and diverse karyotypic changes. Although these current studies focus on the model OVA antigen, the finding that T cells can directly promote genomic instability has important implications for the development of adoptive T cell therapies.
Copyright © 2011 UICC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21935923      PMCID: PMC3903054          DOI: 10.1002/ijc.26447

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  36 in total

1.  Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Richard M Sherry; Suzanne L Topalian; Nicholas P Restifo; Richard E Royal; Udai Kammula; Don E White; Sharon A Mavroukakis; Linda J Rogers; Gerald J Gracia; Stephanie A Jones; David P Mangiameli; Michelle M Pelletier; Juan Gea-Banacloche; Michael R Robinson; David M Berman; Armando C Filie; Andrea Abati; Steven A Rosenberg
Journal:  J Clin Oncol       Date:  2005-04-01       Impact factor: 44.544

Review 2.  Cell transfer immunotherapy for metastatic solid cancer--what clinicians need to know.

Authors:  Steven A Rosenberg
Journal:  Nat Rev Clin Oncol       Date:  2011-08-02       Impact factor: 66.675

3.  Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells.

Authors:  Michael T Spiotto; Hans Schreiber
Journal:  Cancer Immun       Date:  2005-06-06

4.  Combined treatment of a murine breast cancer model with type 5 adenovirus vectors expressing murine angiostatin and IL-12: a role for combined anti-angiogenesis and immunotherapy.

Authors:  S Gyorffy; K Palmer; T J Podor; M Hitt; J Gauldie
Journal:  J Immunol       Date:  2001-05-15       Impact factor: 5.422

5.  Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo.

Authors:  Luis Sanchez-Perez; Timothy Kottke; Rosa Maria Diaz; Atique Ahmed; Jill Thompson; Heung Chong; Alan Melcher; Sheri Holmen; Gregory Daniels; Richard G Vile
Journal:  Cancer Res       Date:  2005-03-01       Impact factor: 12.701

6.  T cell receptor antagonist peptides induce positive selection.

Authors:  K A Hogquist; S C Jameson; W R Heath; J L Howard; M J Bevan; F R Carbone
Journal:  Cell       Date:  1994-01-14       Impact factor: 41.582

7.  Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line.

Authors:  M J Torres; F Ruiz-Cabello; A Skoudy; G Berrozpe; P Jimenez; A Serrano; F X Real; F Garrido
Journal:  Tissue Antigens       Date:  1996-05

8.  Bystander elimination of antigen loss variants in established tumors.

Authors:  Michael T Spiotto; Donald A Rowley; Hans Schreiber
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

9.  Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Authors:  Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas C Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

10.  Escape of mouse mastocytoma P815 after nearly complete rejection is due to antigen-loss variants rather than immunosuppression.

Authors:  C Uyttenhove; J Maryanski; T Boon
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

View more
  33 in total

1.  Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy.

Authors:  Karlo Perica; Joan Glick Bieler; Christian Schütz; Juan Carlos Varela; Jacqueline Douglass; Andrew Skora; Yen Ling Chiu; Mathias Oelke; Kenneth Kinzler; Shibin Zhou; Bert Vogelstein; Jonathan P Schneck
Journal:  ACS Nano       Date:  2015-07-14       Impact factor: 15.881

2.  Generation of CD8(+) T cells expressing two additional T-cell receptors (TETARs) for personalised melanoma therapy.

Authors:  Sandra Höfflin; Sabrina Prommersberger; Ugur Uslu; Gerold Schuler; Christopher W Schmidt; Volker Lennerz; Jan Dörrie; Niels Schaft
Journal:  Cancer Biol Ther       Date:  2015-07-15       Impact factor: 4.742

3.  Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment.

Authors:  Laura Evgin; Amanda L Huff; Timothy Kottke; Jill Thompson; Amy M Molan; Christopher B Driscoll; Matthew Schuelke; Kevin G Shim; Phonphimon Wongthida; Elizabeth J Ilett; Karen Kaluza Smith; Reuben S Harris; Matt Coffey; Jose S Pulido; Hardev Pandha; Peter J Selby; Kevin J Harrington; Alan Melcher; Richard G Vile
Journal:  Cancer Immunol Res       Date:  2019-04-02       Impact factor: 11.151

4.  Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape.

Authors:  Karen M Kaluza; Timothy Kottke; Rosa Maria Diaz; Diana Rommelfanger; Jill Thompson; Richard Vile
Journal:  Hum Gene Ther       Date:  2012-08-13       Impact factor: 5.695

5.  Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy.

Authors:  Aki Furusawa; John Reiser; Kavitha Sadashivaiah; Haley Simpson; Arnob Banerjee
Journal:  J Immunother       Date:  2018 Feb/Mar       Impact factor: 4.456

6.  Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy.

Authors:  Miran Blanchard; Kevin G Shim; Michael P Grams; Karishma Rajani; Rosa M Diaz; Keith M Furutani; Jill Thompson; Kenneth R Olivier; Sean S Park; Svetomir N Markovic; Hardev Pandha; Alan Melcher; Kevin Harrington; Shane Zaidi; Richard Vile
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-07-26       Impact factor: 7.038

7.  DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety.

Authors:  Katrin Friedrich; Jan Rh Hanauer; Steffen Prüfer; Robert C Münch; Iris Völker; Christodoulos Filippis; Christian Jost; Kay-Martin Hanschmann; Roberto Cattaneo; Kah-Whye Peng; Andreas Plückthun; Christian J Buchholz; Klaus Cichutek; Michael D Mühlebach
Journal:  Mol Ther       Date:  2013-02-05       Impact factor: 11.454

8.  CD8+ T-cell responses rapidly select for antigen-negative tumor cells in the prostate.

Authors:  S Peter Bak; Mike Stein Barnkob; K Dane Wittrup; Jianzhu Chen
Journal:  Cancer Immunol Res       Date:  2013-09-20       Impact factor: 11.151

9.  Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.

Authors:  A J Robert McGray; Robin Hallett; Dannie Bernard; Stephanie L Swift; Ziqiang Zhu; Florentina Teoderascu; Heather Vanseggelen; John A Hassell; Arthur A Hurwitz; Yonghong Wan; Jonathan L Bramson
Journal:  Mol Ther       Date:  2013-10-23       Impact factor: 11.454

10.  Systemic combination virotherapy for melanoma with tumor antigen-expressing vesicular stomatitis virus and adoptive T-cell transfer.

Authors:  Diana M Rommelfanger; Phonphimon Wongthida; Rosa M Diaz; Karen M Kaluza; Jill M Thompson; Timothy J Kottke; Richard G Vile
Journal:  Cancer Res       Date:  2012-07-26       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.